Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 1:39:525-541.
doi: 10.1146/annurev-publhealth-040617-013526. Epub 2017 Dec 22.

Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities

Affiliations
Review

Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities

Dennis McCarty et al. Annu Rev Public Health. .

Abstract

Treatment for opioid use disorder in the United States evolved in response to changing federal policy and advances in science. Inpatient care began in 1935 with the US Public Health Service Hospitals in Lexington, Kentucky, and Fort Worth, Texas. Outpatient clinics emerged in the 1960s to provide aftercare. Research advances led to opioid agonist and opioid antagonist therapies. When patients complete opioid withdrawal, return to use is often rapid and frequently deadly. US and international authorities recommend opioid agonist therapy (i.e., methadone or buprenorphine). Opioid antagonist therapy (i.e., extended-release naltrexone) may also inhibit return to use. Prevention efforts emphasize public and prescriber education, use of prescription drug monitoring programs, and safe medication disposal options. Overdose education and naloxone distribution promote access to rescue medication and reduce opioid overdose fatalities. Opioid use disorder prevention and treatment must embrace evidence-based care and integrate with physical and mental health care.

Keywords: opioid agonist therapy; opioid antagonist therapy; opioid overdose prevention; opioid use disorder; treatment for opioid use disorder.

PubMed Disclaimer

References

    1. 21st Century Cures Act, Pub. L. No. 114–255, 130 Stat. 1033 (2016). https://www.congress.gov/bill/114th-congress/house-bill/6/

    1. Deleted in proof

    1. Abraham AJ, Andrews CM, Grogan CM, D’Aunno T, Humphreys KN, et al. The Affordable Care Act transformation of substance use disorder treatment. Am J Public Health. 2017;107:31–32. - PMC - PubMed
    1. Alanis-Hirsch K, Croff R, Ford JH, 2nd, Johnson K, Chalk M, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. J Subst Abuse Treat. 2016;62:68–73. - PMC - PubMed
    1. Albert S, Brawon FW, 2nd, Sanford CK, Dasgupta N, Graham J, Lovette B. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med. 2011;12:S77–85. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources